Signet Ring Cell Carcinoma (SRCC)

Prelims – General Science.

Mains (GS II) - Issues relating to development and management of Social Sector/Services relating to Health, Education, Human Resources.

Why in News?

A team of scientists has developed new ways to better understand and treat signet ring cell carcinoma (SRCC).

It is a rare form of colon cancer (CRC) and is considered one of the deadliest subtypes of the disease.

Colon cancer, also known as colorectal cancer, is a type of cancer that originates in the large intestine (colon) or rectum.

It gets its name from the signet ring-like appearance (a finger ring with a flat top) of its cancer cells under a microscope.
It most commonly develops in the gastrointestinal tract, particularly the stomach, but can also occur in the colon and other organs. It spreads quickly.
Symptoms – Indigestion, Abdominal pain, Nausea and vomiting, Diarrhea, Bloody stools, Fatigue, Joint pain, Pallor (paleness, fast heartbeat and trouble breathing).
Prevalence - CRCs are the 3^rd most common cancer and the 2^nd leading cause of cancer deaths in the world. Globally, this type of cancer constitutes about 1% of all cases of CRC.
It resists conventional therapies, and is often diagnosed at advanced stages.
Severity - It has the tendency to spread to the peritoneum.

The peritoneum is a smooth, transparent membrane that lines the abdominal cavity and covers most of the organs in the abdomen.

Treatment - Surgery, chemotherapy, and other therapies, often used in a multidisciplinary approach.

Recent Findings of the study

Researchers have developed miniature representations of actual human SRCC tumors cultivated in laboratory petri dishes and subsequently implanted into mice.
It provides valuable opportunity to investigate cancer in detail and evaluate potential therapies within a controlled setting.
The research has revealed distinct molecular traits of SRCC that clarify its resistance to conventional chemotherapy.
The research team also explore a variety of drug combinations to identify therapeutic vulnerabilities, specific weaknesses that could be targeted with focused treatments.
Among the most encouraging outcomes of the study was the testing of a novel three-drug combination, which not only reduced tumor size but also inhibited the cancer's progression in laboratory models.